FOR IMMEDIATE RELEASE:

Contact: Cyntellect
Jim Linton, Ph.D.
Chief Business Officer
Phone: (858) 450-7060
Cell: (858) 382-7678
jlinton@cyntellect.com
DDT Conference Booth # 1305

SC Biosciences Corporation
Tsuyoshi Karasawa
Executive Vice President
Phone: 03-5777-6668
e-mail tkarasawa@scbio.co.jp

SC Biosciences Enters Agreement to Distribute Cyntellect's LEAP™ Technology in Japan

Laser-based technology poised to enhance the quality, speed and robustness of cell purification, analysis and transfection. Shipping slated for early 2006.

San Diego, CA and Tokyo, Japan – August 9, 2005 – Cyntellect, Inc. and SC Biosciences ("SCB") today announced the companies have entered into an agreement under which SCB will exclusively distribute Cyntellect's LEAP (**L**aser-**E**nabled **A**nalysis and **P**rocessing) system and certain LEAP-based collaborative services to the life science market in Japan. Under terms of the agreement, SCB has made an equity investment in Cyntellect and has placed an initial purchase order for multiple LEAP units. The companies expect the first LEAP units to be shipped to Japan in early 2006. The agreement represents Cyntellect's first product commercialization agreement for LEAP instrumentation and comes on the heels of the recently announced Cell Xpress service commercialization agreement with Sigma-Aldrich. Cyntellect is showcasing its LEAP technology at the **IBC Drug Discovery Technology (DDT) Conference** in Boston (August 8-11) at **booth # 1305.**

"LEAP's unique combination of automated cell imaging and laser-based cell processing offers important new capabilities to researchers in cell biology, drug discovery and cell sample preparation," said Tsuyoshi Karasawa, Executive Vice President of SC Biosciences. "Our customers in Japan have already expressed strong interest in LEAP as they expect it will enable major new discoveries and increase the productivity of their cell-based research and high-throughput drug discovery efforts."

LEAP is an automated instrument that combines high-speed optical imaging of cells, real-time image analysis and high-speed laser manipulation of individual live cells presented in microplate formats. Using LEAP, researchers can rapidly and selectively laser-irradiate specific cells achieving >99.9% purity. The *in situ* processing nature means researchers can exploit rare cell populations or cells that are typically refractory to currently available purification technologies (e.g. primary cells, patient cells or delicate cell lines) as well as more robust commonly used cell types. LEAP-based laser manipulation of cells has also been demonstrated to effectively permeabilize cells transiently without inducing cellular toxicity. This approach, called LaserFect™, enables introduction of a wide variety of biomolecules including ions, siRNAs, proteins and quantum dots, many of which cannot be transfected using current technologies.

“LEAP represents a paradigm-shift in cell sample preparation that directly addresses the growing, unmet needs for automated purification or transfection of important cell types including patient samples, primary cells and fragile cell types,” stated Jim Linton, Ph.D., Cyntellect’s Chief Business Officer. “With cell-based systems taking center stage in drug discovery and development, LEAP’s ability to enable new scientific studies and streamline workflow will deliver a clear competitive advantage to LEAP customers.”

“This agreement represents a further validation of our LEAP technology and reflects the life science market’s strong appetite for quantum improvements in cell processing,” stated Fred Koller, Ph.D., President and Chief Technical Officer. “We are pleased to establish our first product commercialization relationship in Japan with SC Biosciences, a company that has well-proven expertise in the successful commercialization of cutting edge technologies in the life sciences market.” Dr. Koller added that the Company will be evaluating other potential commercial partners for LEAP on a geographic basis.

About Cyntellect

Cyntellect, Inc. is a biotechnology company committed to revolutionizing the use of living cells in life science research and cellular therapy. The Company combines expertise in high-speed cell imaging and laser-based manipulation to develop products that enable novel cell imaging, purification, and transfection capabilities to enhance the productivity of laboratory research, recombinant protein production, high-content cellular assays, functional genomics and proteomics, and cell purification, including processing of cells for therapeutic transplantation. For additional information please visit the Company’s web site at www.cyntellect.com.

About SC Biosciences

SC BioSciences is a wholly-owned subsidiary of Sumitomo Corporation, which is one of Japan's leading trading companies (founded 1919, employees 5,500, gross trading profit US$4B). SC Biosciences’ mission is to identify and commercially introduce cutting-edge life science technologies, including instrumentation, reagents and platform technologies, into the Japanese marketplace. SC Biosciences has established extensive commercial partnerships with leading life sciences companies including, MDS Sciex, Xenogen, QuantumDot Corporation, Biotage and Curagen. For more information on SC Biosciences, please visit the company website at www.scbio.co.jp.

* * * * * *